DURECT Corp (DRRX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:DURECT Corp (DRRX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7173
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s major products include Alzet, an osmotic pump; and Lactel, a biodegradable polymer. The company’s product pipeline comprises DUR-928 indicated for treatment of acute organ injuries and metabolic/lipid disorders; Remoxy, indicated for chronic pain; Posimir, indicated for post-operative pain; Eladur, indicated for post herpetic neuralgia; Oradur, indicated for chronic pain and attention deficit hyperactivity disorder; and Relday, indicated for Schizophrenia and bipolar disorder. Durect’s major drug delivery technology platforms include Saber, Cloud, Oradur and Transdur. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in California, the US.

DURECT Corp (DRRX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DURECT Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
DURECT Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
DURECT Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
DURECT Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
DURECT Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
DURECT Corp, Medical Equipment, Deal Details 10
Partnerships 10
Durect Enters into Licensing Agreement with Santen Pharma 10
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 11
Equity Offering 12
Durect Plans to Raise up to USD175 Million in Public Offering of Securities 12
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 13
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 14
Durect Completes Public Offering Of Shares For US$11.5 Million 15
Durect Completes Public Offering Of Shares For US$13 Million 16
DURECT Corp – Key Competitors 17
DURECT Corp – Key Employees 18
DURECT Corp – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Aug 01, 2018: DURECT announces second quarter 2018 financial results and provides corporate update 20
May 02, 2018: DURECT Reports First Quarter 2018 Financial Results 22
Mar 01, 2018: DURECT Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs 24
Nov 01, 2017: DURECT Announces Third Quarter 2017 Financial Results and Provides Corporate Update 26
Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 28
May 10, 2017: DURECT Announces First Quarter 2017 Financial Results and Provides Corporate Update 30
Mar 14, 2017: DURECT Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs 32
Corporate Communications 34
Oct 01, 2018: DURECT names Michael H. Arenberg as Chief Financial Officer 34
Oct 01, 2018: DURECT names Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer 35
Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
DURECT Corp, Medical Equipment, Key Facts, 2017 2
DURECT Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
DURECT Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
DURECT Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
DURECT Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
DURECT Corp, Deals By Market, 2012 to YTD 2018 8
DURECT Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Durect Enters into Licensing Agreement with Santen Pharma 10
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 11
Durect Plans to Raise up to USD175 Million in Public Offering of Securities 12
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 13
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 14
Durect Completes Public Offering Of Shares For US$11.5 Million 15
Durect Completes Public Offering Of Shares For US$13 Million 16
DURECT Corp, Key Competitors 17
DURECT Corp, Key Employees 18

List of Figures
DURECT Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
DURECT Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
DURECT Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
DURECT Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
DURECT Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
DURECT Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
DURECT Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[DURECT Corp (DRRX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Portigon Ag:企業の戦略・SWOT・財務分析
    Portigon Ag - Strategy, SWOT and Corporate Finance Report Summary Portigon Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Egdon Resources Plc (EDR):石油・ガス:M&Aディール及び事業提携情報
    Summary Egdon Resources Plc (Egdon) is oil and gas company that offers exploration and production services. The company explores and develops petroleum and natural gas assets in East Midlands, North East England, North West England, and Southern England, the UK. Its project site includes Wressle, No …
  • Fiat Chrysler Automobiles NV:企業の戦略・SWOT・財務情報
    Fiat Chrysler Automobiles NV - Strategy, SWOT and Corporate Finance Report Summary Fiat Chrysler Automobiles NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Celulose Irani S.A.:企業の戦略・SWOT・財務情報
    Celulose Irani S.A. - Strategy, SWOT and Corporate Finance Report Summary Celulose Irani S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • BioMark Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company that owns and develops multiple intellectual properties in detection and quantitation of metabolites. The company’s advanced near-to- market diagnostic technologies designed to improve patient outc …
  • WSI Industries, Inc.:企業の戦略・SWOT・財務情報
    WSI Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary WSI Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • J. C. Penney Company, Inc.:企業の戦略・SWOT・財務情報
    J. C. Penney Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary J. C. Penney Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Innovative Med Concepts LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Innovative Med Concepts LLC (Innovative Med Concepts) is a biotech company that develops novel treatments for the treatment of fibromyalgia and other related syndromes. The company’s pipeline products include NRP-1, a throat spray which is used to treat viral pharyngitis that provides relief …
  • Hopewell Holdings Ltd (54):企業の財務・戦略的SWOT分析
    Hopewell Holdings Ltd (54) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NicOx SA (COX)-医療機器分野:企業M&A・提携分析
    Summary NicOx SA (NicOx) is an pharmaceutical company that develops ophthalmic portfolio of therapies and diagnostic tools. The company offers ophthalmic products which include AdenoPlus, AzaSite, BromSite, Xailin, Vesneo, next generation NO-donors and Syk and JAK inhibitors, and others. It offers p …
  • Tata Steel Europe Ltd:企業の戦略・SWOT・財務情報
    Tata Steel Europe Ltd - Strategy, SWOT and Corporate Finance Report Summary Tata Steel Europe Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Interprotein Corp-製薬・医療分野:企業M&A・提携分析
    Summary Interprotein Corp (Interprotein) is a drug discovery company that conducts research and develops small molecule drugs. The company provides IL-6 inhibitor, IgE inhibitor, notch1 inhibitor, tubulin polymerization inhibitors, TIM-3 inhibitor, NKG2A, HLA-E and CD94 inhibitor; KIR and HLA-C inhi …
  • Verax Biomedical Inc-製薬・医療分野:企業M&A・提携分析
    Summary Verax Biomedical Inc (Verax) is a medical device company that develops rapid tests for the detection of bacterial contaminants in tissues for transplantation, blood components, and cellular therapies. The company’s products comprise platelet pgd test, red cell pgd test and cell therapy PGD t …
  • CohBar Inc (COB.U):企業の財務・戦略的SWOT分析
    Summary CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and C …
  • Bulgarian Energy Holding EAD:企業の戦略的SWOT分析
    Bulgarian Energy Holding EAD - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Sectra AB (SECT B)
    Sectra AB (SECT B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Biomay AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Biomay AG (Biomay) is a developer of therapeutics for allergy that discovers disease modifying allergy therapeutics. The company develops peptide carrier fusion vaccines for allergy immunotherapy. It provides pipeline product portfolio such as investigation candidates targeted against IgE me …
  • Visa Inc:企業のM&A・事業提携・投資動向
    Visa Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Visa Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Snap-on Incorporated (SNA):企業の財務・戦略的SWOT分析
    Snap-on Incorporated (SNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Wilmar International Ltd (F34):企業の財務・戦略的SWOT分析
    Wilmar International Ltd (F34) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆